Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459585 · ClinicalTrials.gov registry record · Early Phase 1
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
A Early Phase 1 study, sponsored by Daiichi Sankyo Co..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04459585 is a Early Phase 1 study that has completed, run by Daiichi Sankyo Co.. The registered enrollment target is 20 participants.
The verdict
NCT04459585, a Early Phase 1 study, has completed, sponsored by Daiichi Sankyo Co..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the one-way drug-drug interaction potential of quizartinib on dabigatran etexilate in healthy adult participants.
Interventions
- DRUG Quizartinib
- DRUG Dabigatran Etexilate Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2020-10-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459585
The ClinicalTrials.gov registry entry for NCT04459585 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quizartinib is the first listed.
NCT04459585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04459585 about?
NCT04459585 is a clinical study titled "A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants". The purpose of this study is to investigate the one-way drug-drug interaction potential of quizartinib on dabigatran etexilate in healthy adult participants.
What is the current status of trial NCT04459585?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-08-28. Estimated completion is 2020-10-20.
What interventions are being tested in trial NCT04459585?
The interventions under investigation include: Quizartinib (DRUG), Dabigatran Etexilate Mesylate (DRUG).
Who is sponsoring clinical trial NCT04459585?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.